Customer testimonials
François NICOLI MD, PhD
Former Head of the Stroke Center of La Timone University Hospital in Marseille, France
— “My friend Fayçal DJERIDANE, CEO of Olea Medical, and I started to work on answering the needs in stroke care fifteen years ago, when we met during a research activity led in a department with full access to MRI scanner (DWI/PWI, NMR spectroscopy / Metabolic Cerebral Imaging, …). I’ve been in charge of a research protocol on acute stroke imaging using MRI from many years now. In my clinical practice, I have managed more than 400 IV-thrombolysis, following an exclusive MRI selection, and conducted emergency MRI on more than 1500 potential stroke patients, over the last 5 years. I have personally treated and followed all these stroke patients, from the acute stage to 3 months and beyond following their stroke. Thanks to my radiologist colleagues, present in our University Hospital facility, for more than 5 years, my patients, potential candidates for thrombolysis, have a permanent and free access to MRI, the best tool in the hands of neurologists to explore the brain. My main goal has been to share my extensive knowledge in acute stroke care management by designing a tool physicians can use in a clinical setting and that allows them to make the best and fastest decision to the sole benefit of patient. Olea Medical has given me the opportunity to do so beyond all my expectations. My hope is that the easiness and rapidity of utilization, which these software solutions offer, permit to increase the access to MRI for patients with acute stroke.
Marseille, December 4th 2009.”
Marc FISHER MD
— “The PerfScape™ and NeuroScape™ software provide excellent platforms for the rapid evaluation of MRI data in acute stroke patients, providing reliable and quantitative information about the extent and location of the diffusion/perfusion mismatch.”
Kenneth BUTCHER MD, PhD
— “PerfScape™ and NeuroScape™ allow us to generate easily interpretable perfusion maps in real time. Importantly, they provide us with objective measurements of hypoperfused tissue volume. These quantitative measures allow us to make objective assessments of the potential for tissue salvage in acute stroke patients.”